Regeneron and CytomX extend cancer therapy partnership to $4bn deal.

{
  "signal_id": "ddcb5ef8-e3b7-441c-bc9a-4aa1c2074b5b",
  "signal_type": "news",
  "signal_subtype": "is_developing",
  "detected_at": "2026-06-04T08:21:36+00:00",
  "company": {
    "name": "Regeneron",
    "domain": "regeneron.com"
  },
  "data": {
    "url": "https://pharmaceutical-business-review.com/news/regeneron-cytomx-cancer-therapy-partnership",
    "title": "Regeneron and CytomX extend cancer therapy partnership to $4bn deal.",
    "excerpt": "Regeneron and CytomX extend cancer therapy partnership to $4bn deal.\n\nRecommended companies.\n\nRegeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with the deal's total potential value rising to up to $4bn.\n\nThe collaboration combines CytomX's Probody technology with Regeneron's Veloci-Bi bispecific platform to target hard-to-treat tumour types.\n\nEstablished in 2022, the partnership combines CytomX's biologic masking technology with Regeneron's expertise in bispecific antibodies.\n\nThe therapies are designed to stay inactive until proteases in the tumour microenvironment activate them, aiming to improve both the safety and effectiveness of T-cell engager treatments.\n\nThis approach seeks to address tumour types that have proven difficult for conventional immunotherapy.\n\nRegeneron oncology and antibody technology research senior vice-president John Lin said: \"Cancer necessitates innovative treatment approaches, and with this expanded collaboration with CytomX, we are advancing bispecific treatments where we see the most promise.\n\n\"Our complementary oncology expertise with CytomX, including application of our proprietary VelociSuite technologies developed to accelerate drug discovery and development, makes us uniquely suited to work together on this endeavour to bring...",
    "product": "conditionally activated bispecific antibody cancer therapies",
    "summary": "Regeneron is developing conditionally activated bispecific antibody cancer therapies on Jul 1st '22.",
    "category": "is_developing",
    "found_at": "2026-06-04T08:21:36Z",
    "planning": false,
    "image_url": "https://pharmaceutical-business-review.com/wp-content/uploads/2026/06/PT-04-06-2026-shutterstock_1942059757.jpg",
    "confidence": 0.431,
    "product_data": {
      "full_text": "conditionally activated bispecific antibody cancer therapies",
      "fuzzy_match": true
    },
    "published_at": "2026-06-04T09:50:06Z",
    "effective_date": "2022-07-01",
    "article_sentence": "Regeneron Pharmaceuticals and CytomX have expanded their research and licensing partnership to develop conditionally activated bispecific antibody cancer therapies, with the deal's total potential value rising to up to $4bn."
  }
}

curl https://signals.autobound.ai/v1/signals/ddcb5ef8-e3b7-441c-bc9a-4aa1c2074b5b \
  -H "X-API-KEY: $AUTOBOUND_API_KEY"

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"regeneron.com","limit":20}'